Clinical Relevance of Biomarkers of Oxidative Stress

Antioxidants and Redox Signaling

Volumn 23, Issue 14, 2015, Pages 1144-1170

  Frijhoff, Jeroen ^a   Winyard, Paul G ^b   Zarkovic, Neven ^c   Davies, Sean S ^d,e   Stocker, Roland ^f,g   Cheng, David ^f   Knight, Annie R ^b   Taylor, Emma Louise ^b   Oettrich, Jeannette ^a   Ruskovska, Tatjana ^h   Gasparovic, Ana Cipak ^c   Cuadrado, Antonio ^i,j,k,l   Weber, Daniela ^m   Poulsen, Henrik Enghusen ^n,o   Grune, Tilman ^m   Schmidt, Harald H H W ^a   Ghezzi, Pietro ^p  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c RUDER BO KOVI INSTITUTE   (Croatia)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h GOCE DELCEV UNIVERSITY   (Macedonia)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^l AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^m GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o FREDERIKSBERG HOSPITAL   (Denmark)

^p BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; ARGININE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CYSTEINE; DISULFIDE; DNA; GLUTATHIONE; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; METHIONINE SULFOXIDE; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; RNA; THIOL; TRANSCRIPTION FACTOR NRF2; XANTHINE OXIDASE; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; CHEMICAL MODIFICATION; DNA RNA HYBRIDIZATION; HUMAN; LIPID OXIDATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; DNA DAMAGE; LIPID PEROXIDATION; METABOLISM; PROTEIN CARBONYLATION;

ANIMALS; BIOMARKERS; DNA DAMAGE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; REACTIVE OXYGEN SPECIES;

EID: 84947743712     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6317     Document Type: Review

References (201)

1. Abbasi A, Corpeleijn E, Gansevoort RT, Gans ROB, Struck J, Schulte J, Hillege HL, van der Harst P, Stolk RP, Navis G, and Bakker SJL. Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 57: 1842-1849, 2014.
2. Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch J-P, Bode C, Schmidt HHHW, and Peter K. Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 218: 431-434, 2011.
3. Alvarez B and Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25: 295-311, 2003.
4. Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858-6862, 1981.
5. Andresen M, Regueira T, Bruhn A, Perez D, Strobel P, Dougnac A, Marshall G, and Leighton F. Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock. Mediators Inflamm 2008: 168652-168658, 2008.
6. Atkuri KR, Mantovani JJ, Herzenberg LA, and Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7: 355-359, 2007.
7. Awad JA, Morrow JD, Takahashi K, and Roberts LJ. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem 268: 4161-4169, 1993.
8. Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu C-H, Kirkpatrick DL, and Powis G. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 147: 83-90, 2006.
9. Baker JR, Metcalf PA, Johnson RN, Newman D, and Rietz P. Use of protein-based standards in automated colorimetric determinations of fructosamine in serum. Clin Chem 31: 1550-1554, 1985.
10. Barregard L, Møller P, Henriksen T, Mistry V, Koppen G, Rossner P, Sram RJ, Weimann A, Poulsen HE, Nataf R, Andreoli R, Manini P, Marczylo T, Lam P, Evans MD, Kasai H, Kawai K, Li Y-S, Sakai K, Singh R, Teichert F, Farmer PB, Rozalski R, Gackowski D, Siomek A, Saez GT, Cerda C, Broberg K, Lindh C, Hossain MB, Haghdoost S, Hu C-W, Chao M-R, Wu K-Y, Orhan H, Senduran N, Smith RJ, Santella RM, Su Y, Cortez C, Yeh S, Olinski R, Loft S, and Cooke MS. Human and methodological sources of variability in the measurement of urinary 8-oxo-7,8-dihydro-2¢-deoxyguanosine. Antioxid Redox Signal 18: 2377-2391, 2013.
11. Bartesaghi S, Ferrer-Sueta G, Peluffo G, Valez V, Zhang H, Kalyanaraman B, and Radi R. Protein tyrosine nitration in hydrophilic and hydrophobic environments. Amino Acids 32: 501-515, 2006.
12. Battelli MG, Bolognesi A, and Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta 1842: 1502-1517, 2014.
13. Bayer SB, Maghzal G, Stocker R, Hampton MB, and Winterbourn CC. Neutrophil-mediated oxidation of erythrocyte peroxiredoxin 2 as a potential marker of oxidative stress in inflammation. FASEB J 27: 3315-3322, 2013.
14. Bäck M and Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 12: 199-211, 2015.
15. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, and Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101: 13032-13037, 2004.
16. Bowry VW, Stanley KK, and Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 89: 10316-10320, 1992.
17. Brame CJ, Boutaud O, Davies SS, Yang T, Oates JA, Roden D, and Roberts LJ. Modification of proteins by isoketal-containing oxidized phospholipids. J Biol Chem 279: 13447-13451, 2004.
18. Brame CJ, Salomon RG, Morrow JD, and Roberts LJ. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 274: 13139-13146, 1999.
19. Breusing N, Grune T, Andrisic L, Atalay M, Bartosz G, Biasi F, Borovic S, Bravo L, Casals I, Casillas R, Dinischiotu A, Drzewinska J, Faber H, Fauzi NM, Gajewska A, Gambini J, Gradinaru D, Kokkola T, Lojek A, Luczaj W, Margina D, Mascia C, Mateos R, Meinitzer A, Mitjavila MT, Mrakovcic L, Munteanu MC, Podborska M, Poli G, Sicinska P, Skrzydlewska E, Vina J, Wiswedel I, Zarkovic N, Zelzer S, and Spickett CM. An interlaboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples. Free Radic Res 44: 1203-1215, 2010.
20. Brix JM, Höllerl F, Kopp H-P, Schernthaner GH, and Schernthaner G. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity. Int J Obes (Lond) 36: 1412-1417, 2012.
21. Brock JWC, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, (DCCT/EDIC) Research Group, Thorpe SR, and Baynes JW. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 49: 847-855, 2008.
22. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT, Jimenez-Solem E, Hansen LJ, Henriksen JE, Bonnema SJ, de Fine Olivarius N, Friis S, and Poulsen HE. Urinary markers of nucleic acid oxidation and cancer in type 2 diabetes. Redox Biol 4C: 34-39, 2014.
23. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT, Jimenez-Solem E, Stovgaard ES, Hansen LJ, Henriksen JE, Bonnema SJ, Olivarius Nde F, and Poulsen HE. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care 34: 2594-2596, 2011.
24. Buss H, Chan TP, Sluis KB, Domigan NM, and Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 23: 361-366, 1997.
25. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000.
26. Calabretta A, Küpfer PA, and Leumann CJ. The effect of RNA base lesions on mRNA translation. Nucleic Acids Res 43: 4713-4720, 2015.
27. Carp H, Miller F, Hoidal JR, and Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 79: 2041-2045, 1982.
28. Ceriello A, Esposito K, Piconi L, Ihnat M, Thorpe J, Testa R, Bonfigli AR, and Giugliano D. Glucose "peak" and glucose "spike": impact on endothelial function and oxidative stress. Diabetes Res Clin Pract 82: 262-267, 2008.
29. Ceriello A, Kumar S, Piconi L, Esposito K, and Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30: 649-654, 2007.
30. Checconi P, Salzano S, Bowler L, Mullen L, Mengozzi M, Hanschmann E-M, Lillig CH, Sgarbanti R, Panella S, Nencioni L, Palamara AT, and Ghezzi P. Redox proteomics of the inflammatory secretome identifies a common set of redoxins and other glutathionylated proteins released in inflammation, influenza virus infection and oxidative stress. PLoS One 10: e0127086, 2015.
31. Chen H-JC, Lin W-P, Chiu S-D, and Fan C-H. Multistage mass spectrometric analysis of human hemoglobin glutathionylation: correlation with cigarette smoking. Chem Res Toxicol 27: 864-872, 2014.
32. Choi D-K, Pennathur S, Perier C, Tieu K, Teismann P, Wu D-C, Jackson-Lewis V, Vila M, Vonsattel J-P, Heinecke JW, and Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25: 6594-6600, 2005.
33. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, and Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 52: 601-623, 2006.
34. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329: 23-38, 2003.
35. Daugherty A, Dunn JL, Rateri DL, and Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444, 1994.
36. Davies SS, Amarnath V, Montine KS, Bernoud-Hubac N, Boutaud O, Montine TJ, and Roberts LJ. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J 16: 715-717, 2002.
37. Davies SS, Amarnath V, and Roberts LJ. Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway. Chem Phys Lipids 128: 85-99, 2004.
38. Davies SS, Bodine C, Matafonova E, Pantazides BG, Bernoud-Hubac N, Harrison FE, Olson SJ, Montine TJ, Amarnath V, and Roberts LJ. Treatment with a cketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. J Alzheimers Dis 27: 49-59, 2011.
39. Davies SS and Roberts LJ. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 50: 559-566, 2011.
40. Dean RT, Fu S, Stocker R, and Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 324 (Pt 1): 1-18, 1997.
41. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, and Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002.
42. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
43. Di Giuseppe D, Di Simplicio P, Capecchi PL, Lazzerini PE, and Pasini FL. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med 142: 21-28, 2003.
44. Dildar K, Sinem F, Gökhan E, Orhan Y, and Filiz M. Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis Assoc Disord 24: 194-197, 2010.
45. Duncan MW. A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids 25: 351-361, 2003.
46. Eck HP, Gmünder H, Hartmann M, Petzoldt D, Daniel V, and Dröge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler 370: 101-108, 1989.
47. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA J 9: 2474-2486, 2011.
48. Enroth C, Eger BT, Okamoto K, Nishino T, and Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA 97: 10723-10728, 2000.
49. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991.
50. Foster DB, Van Eyk JE, Marbán E, and O'Rourke B. Redox signaling and protein phosphorylation in mitochondria: progress and prospects. J Bioenerg Biomembr 41: 159-168, 2009.
51. Friedman P, Horkko S, Steinberg D, Witztum JL, and Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 277: 7010-7020, 2002.
52. Friess U, Waldner M, Wahl HG, Lehmann R, Haring HU, Voelter W, and Schleicher E. Liquid chromatographybased determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects. J Chromatogr B Analyt Technol Biomed Life Sci 794: 273-280, 2003.
53. Frijhoff J, Dagnell M, Godfrey R, and Ostman A. Regulation of protein tyrosine phosphatase oxidation in cell adhesion and migration. Antioxid Redox Signal 20: 1994-2010, 2014.
54. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, and Bonassi S. Oxidative stressrelated biomarkers in autism: systematic review and metaanalyses. Free Radic Biol Med 52: 2128-2141, 2012.
55. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, and Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986, 1996.
56. Fukuda K, Davies SS, Nakajima T, Ong B-H, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, Boyden PA, Viswanathan PC, Roberts LJ, and Balser JR. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97: 1262-1269, 2005.
57. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, and Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51: 957-965, 2005.
58. Ghezzi P. Protein glutathionylation in health and disease. Biochim Biophys Acta 1830: 3165-3172, 2013.
59. Ghezzi P, Bianchi M, Mantovani A, Spreafico F, and Salmona M. Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochem Biophys Res Commun 119: 144-149, 1984.
60. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989, 2000.
61. Gil L, Siems W, Mazurek B, Gross J, Schroeder P, Voss P, and Grune T. Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res 40: 495-505, 2006.
62. Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F, Fuchs D, and Oettl K. Malondialdehyde, carbonyl proteins and albumindisulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 42: 633-638, 2008.
63. Guéraud F, Taché S, Steghens J-P, Milkovic L, Borovic-Sunjic S, Zarkovic N, Gaultier E, Naud N, Héliès-Toussaint C, Pierre F, and Priymenko N. Dietary polyunsaturated fatty acids and heme iron induce oxidative stress biomarkers and a cancer promoting environment in the colon of rats. Free Radic Biol Med 83: 192-200, 2015.
64. Guo L, Amarnath V, and Davies SS. A liquid chromatography-tandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines. Anal Biochem 405: 236-245, 2010.
65. Guo L, Chen Z, Cox BE, Amarnath V, Epand RF, Epand RM, and Davies SS. Phosphatidylethanolamines modified by c-ketoaldehyde (cKA) induce endoplasmic reticulum stress and endothelial activation. J Biol Chem 286: 18170-18180, 2011.
66. Haehling von S, Bode-Böger SM, Martens-Lobenhoffer J, Rauchhaus M, Schefold JC, Genth-Zotz S, Karhausen T, Cicoira M, Anker SD, and Doehner W. Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther 88: 506-512, 2010.
67. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, Feller-Kopman D, Wise R, and Biswal S. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 3: 78ra32, 2011.
68. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
69. This reference has been deleted.
70. Henderson PT, Evans MD, and Cooke MS. Salvage of oxidized guanine derivatives in the (2¢-deoxy)ribonucleotide pool as source of mutations in DNA. Mutat Res 703: 11-17, 2010.
71. Herce-Pagliai C, Kotecha S, and Shuker DE. Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Nitric Oxide 2: 324-336, 1998.
72. Herzenberg LA, Parks D, Sahaf B, Perez O, Roederer M, and Herzenberg LA. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem 48: 1819-1827, 2002.
73. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, and Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76: 663-669, 1996.
74. Hool LC and Corry B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal 9: 409-435, 2007.
75. Huang C-F, Zhang L, Ma S-R, Zhao Z-L, Wang W-M, He K-F, Zhao Y-F, Zhang W-F, Liu B, and Sun Z-J. Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma. PLoS One 8: e83479, 2013.
76. Hwang C, Sinskey AJ, and Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 257: 1496-1502, 1992.
77. Ibarra-Alvarado C, Galle J, Melichar VO, Mameghani A, and Schmidt HHHW. Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol Pharmacol 61: 312-319, 2002.
78. Il'yasova D, Morrow JD, Ivanova A, and Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol 14: 793-797, 2004.
79. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, and Yamamoto M. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 103: 760-766, 2012.
80. Ishii T, Warabi E, and Yanagawa T. Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. J Clin Biochem Nutr 50: 91-105, 2012.
81. Itabe H and Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14: 1-11, 2007.
82. Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, Imanaka T, and Takano T. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 271: 33208-33217, 1996.
83. Janssen-Heininger YMW, Mossman BT, Heintz NH, Forman HJ, Kalyanaraman B, Finkel T, Stamler JS, Rhee SG, and van der Vliet A. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med 45: 1-17, 2008.
84. Ji L, Wei Y, Jiang T, and Wang S. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int J Clin Exp Pathol 7: 1124-1131, 2014.
85. Johnson D and Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem 254: 4022-4026, 1979.
86. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, and Sternberg P. Redox state of glutathione in human plasma. Free Radic Biol Med 28: 625-635, 2000.
87. Jones DP and Go Y-M. Mapping the cysteine proteome: analysis of redox-sensing thiols. Curr Opin Chem Biol 15: 103-112, 2011.
88. Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Greisen Soendergaard M, Henriksen T, Weimann A, Jepsen P, Lykkesfeldt J, Poulsen HE, and Balslev Jorgensen M. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res 209: 417-423, 2013.
89. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, and Barrett JC. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning Free Radic Biol Med 38: 698-710, 2005.
90. Kaplowitz N, Fernández-Checa JC, Kannan R, Garcia-Ruiz C, Ookhtens M, and Yi JR. GSH transporters: molecular characterization and role in GSH homeostasis. Biol Chem Hoppe Seyler 377: 267-273, 1996.
91. Keller RJ, Halmes NC, Hinson JA, and Pumford NR. Immunochemical detection of oxidized proteins. Chem Res Toxicol 6: 430-433, 1993.
92. Kettle AJ, Albrett AM, Chapman AL, Dickerhof N, Forbes LV, Khalilova I, and Turner R. Measuring chlorine bleach in biology and medicine. Biochim Biophys Acta 1840: 781-793, 2014.
93. Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman ALP, Mocatta TJ, and Wagener JS. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 170: 1317-1323, 2004.
94. Khan J, Brennand D, Bradley N, Gao B, Bruckdorfer R, and Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 332 (Pt 3): 807-808, 1998.
95. Kirabo A, Fontana V, de Faria APC, Loperena R, Galindo CL, Wu J, Bikineyeva AT, Dikalov S, Xiao L, Chen W, Saleh MA, Trott DW, Itani HA, Vinh A, Amarnath V, Amarnath K, Guzik TJ, Bernstein KE, Shen XZ, Shyr Y, Chen S-C, Mernaugh RL, Laffer CL, Elijovich F, Davies SS, Moreno H, Madhur MS, Roberts J, and Harrison DG. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest 124: 4642-4656, 2014.
96. Kondo N, Ishii Y, Kwon Y-W, Tanito M, Horita H, Nishinaka Y, Nakamura H, and Yodoi J. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 172: 442-448, 2004.
97. Kunert C, Skurk T, Frank O, Lang R, Hauner H, and Hofmann T. Development and application of a stable isotope dilution analysis for the quantitation of advanced glycation end products of creatinine in biofluids of type 2 diabetic patients and healthy volunteers. Anal Chem 85: 2961-2969, 2013.
98. Laragione T, Gianazza E, Tonelli R, Bigini P, Mennini T, Casoni F, Massignan T, Bonetto V, and Ghezzi P. Regulation of redox-sensitive exofacial protein thiols in CHO cells. Biol Chem 387: 1371-1376, 2006.
99. Leiper J, Murray-Rust J, McDonald N, and Vallance P. Snitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99: 13527-13532, 2002.
100. Leiper J and Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 10: 277-291, 2011.
101. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, and Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186: 464-478, 1990.
102. Li W, Laird JM, Lu L, Roychowdhury S, Nagy LE, Zhou R, Crabb JW, and Salomon RG. Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts. Free Radic Biol Med 47: 1539-1552, 2009.
103. Loft S, Olsen A, Møller P, Poulsen HE, and Tjønneland A. Association between 8-oxo-7,8-dihydro-2¢-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study. Cancer Epidemiol Biomarkers Prev 22: 1289-1296, 2013.
104. Loft S and Poulsen HE. Markers of oxidative damage to DNA: antioxidants and molecular damage. Methods Enzymol 300: 166-184, 1999.
105. Loft S, Svoboda P, Kawai K, Kasai H, Sørensen M, Tjønneland A, Vogel U, Møller P, Overvad K, and Raaschou-Nielsen O. Association between 8-oxo-7,8-dihydroguanine excretion and risk of lung cancer in a prospective study. Free Radic Biol Med 52: 167-172, 2012.
106. Manevich Y, Hutchens S, Halushka PV, Tew KD, Townsend DM, Jauch EC, and Borg K. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med 72: 210-221, 2014.
107. Martinon F, Pétrilli V, Mayor A, Tardivel A, and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241, 2006.
108. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312: 159-163, 1985.
109. McCord JM and Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 243: 5753-5760, 1968.
110. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar H S A, and Schmidt HHHW. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 101: 16671-16676, 2004.
111. Mengozzi M, Ermilov P, Annenkov A, Ghezzi P, and Pearl F. Definition of a family of tissue-protective cytokines using functional cluster analysis: a proof-of-concept study. Front Immunol 5: 115, 2014.
112. Mihm MJ, Jing L, Bauer JA. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 36: 182-187, 2000.
113. Mills BJ, Weiss MM, Lang CA, Liu MC, and Ziegler C. Blood glutathione and cysteine changes in cardiovascular disease. J Lab Clin Med 135: 396-401, 2000.
114. Milne GL, Dai Q, and Roberts LJ. The isoprostanes-25 years later. Biochim Biophys Acta 1851: 433-445, 2014.
115. Milne GL, Sanchez SC, Musiek ES, and Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2: 221-226, 2007.
116. Milne GL, Yin H, Hardy KD, Davies SS, and Roberts LJ. Isoprostane generation and function. Chem Rev 111: 5973-5996, 2011.
117. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, and Maeda K. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7: 1198-1206, 1996.
118. Moore K and Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 28: 659-671, 1998.
119. Moriarty-Craige SE and Jones DP. Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr 24: 481-509, 2004.
120. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990.
121. Morrow JD, Roberts LJ, Daniel VC, Awad JA, Mirochnitchenko O, Swift LL, and Burk RF. Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo-effects of oxygen tension and glutathione. Arch Biochem Biophys 353: 160-171, 1998.
122. Murri M, Luque-Ramrez M, Insenser M, Ojeda-Ojeda M, and Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 19: 268-288, 2013.
123. Mutlu-Türkog lu U, Ilhan E, Oztezcan S, Kuru A, Aykaç-Toker G, and Uysal M. Age-related increases in plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in elderly subjects. Clin Biochem 36: 397-400, 2003.
124. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, and Reynolds WF. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78: 97-107, 1997.
125. Nagumo K, Tanaka M, Chuang VTG, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, and Maruyama T. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS One 9: e85216, 2014.
126. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA, and Herzenberg LA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98: 2688-2693, 2001.
127. Negre-Salvayre A, Auge N, Ayala V, Basaga H, Boada J, Brenke R, Chapple S, Cohen G, Feher J, Grune T, Lengyel G, Mann GE, Pamplona R, Poli G, Portero-Otin M, Riahi Y, Salvayre R, Sasson S, Serrano J, Shamni O, Siems W, Siow RCM, Wiswedel I, Zarkovic K, and Zarkovic N. Pathological aspects of lipid peroxidation. Free Radic Res 44: 1125-1171, 2010.
128. Ng F, Berk M, Dean O, and Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11: 851-876, 2008.
129. This reference has been deleted.
130. Onodera Y, Motohashi H, Takagi K, Miki Y, Shibahara Y, Watanabe M, Ishida T, Hirakawa H, Sasano H, Yamamoto M, and Suzuki T. NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocr Relat Cancer 21: 241-252, 2014.
131. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, and Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 27: 1080-1086, 1999.
132. Pedersen-Lane JH, Zurier RB, and Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol 81: 934-941, 2007.
133. Peluffo G and Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 75: 291-302, 2007.
134. Poulsen HE, Nadal LL, Broedbaek K, Nielsen PE, and Weimann A. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochim Biophys Acta 1840: 801-808, 2014.
135. Poulsen HE, Prieme H, and Loft S. Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 7: 9-16, 1998.
136. Poulsen HE, Specht E, Broedbaek K, Henriksen T, Ellervik C, Mandrup-Poulsen T, Tonnesen M, Nielsen PE, Andersen HU, and Weimann A. RNA modifications by oxidation: a novel disease mechanism Free Radic Biol Med 52: 1353-1361, 2012.
137. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 50: 716-722, 2009.
138. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, and Puddey IB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 272: 209-215, 1999.
139. Qi A-Q, Li Y, Liu Q, Si J-Z, Tang X-M, Zhang Z-Q, Qi Q-D, and Chen W-B. Thioredoxin is a novel diagnostic and prognostic marker in patients with ischemic stroke. Free Radic Biol Med 80: 129-135, 2015.
140. Radi R. Peroxynitrite, a stealthy biological oxidant. J Biol Chem 288: 26464-26472, 2013.
141. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, and Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155: 31-41, 1999.
142. Roberts LJ, Fessel JP, and Davies SS. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol 15: 143-148, 2005.
143. Roberts LJ and Morrow JD. Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 59: 808-820, 2002.
144. Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and Cuadrado A. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal 21: 2498-2514, 2014.
145. Ryberg H, Söderling A-S, Davidsson P, Blennow K, Caidahl K, and Persson LI. Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer's disease. Neurochem Int 45: 57-62, 2004.
146. Sabuncu T, Vural H, and Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34: 407-413, 2001.
147. Sahaf B, Heydari K, Herzenberg LA, and Herzenberg LA. The extracellular microenvironment plays a key role in regulating the redox status of cell surface proteins in HIVinfected subjects. Arch Biochem Biophys 434: 26-32, 2005.
148. Salomon R and Bi W. Isolevuglandin adducts in disease. Antioxid Redox Signal 22: 1703-1718, 2015.
149. Salomon RG. Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways. Chem Phys Lipids 134: 1-20, 2005.
150. Salomon RG. Levuglandins and isolevuglandins: stealthy toxins of oxidative injury. Antioxid Redox Signal 7: 185-201, 2005.
151. Salomon RG, Jirousek MR, Ghosh S, and Sharma RB. Prostaglandin endoperoxides 21. Covalent binding of levuglandin E2 with proteins. Prostaglandins 34: 643-656, 1987.
152. Salomon RG and Miller DB. Levuglandins: isolation, characterization, and total synthesis of new secoprostanoid products from prostaglandin endoperoxides. Adv Prostaglandin Thromboxane Leukot Res 15: 323-326, 1985.
153. Salzano S, Checconi P, Hanschmann E-M, Lillig CH, Bowler LD, Chan P, Vaudry D, Mengozzi M, Coppo L, Sacre S, Atkuri KR, Sahaf B, Herzenberg LA,Herzenberg LA,Mullen L, andGhezzi P. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci USA 111: 12157-12162, 2014.
154. Schieber M and Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 24: R453-R462, 2014.
155. Schneider R, Raff U, Vornberger N, Schmidt M, Freund R, Reber M, Schramm L, Gambaryan S, Wanner C, Schmidt HHHW, and Galle J. L-arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney Int 64: 216-225, 2003.
156. Schramm L, La M, Heidbreder E, Hecker M, Beckman JS, Lopau K, Zimmermann J, Rendl J, Reiners C, Winderl S, Wanner C, and Schmidt HHHW. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int 61: 1423-1432, 2002.
157. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmüller S, Walter U, Reichenspurner H, Meinertz T, and Münzel T. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105: 1170-1175, 2002.
158. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 27: 916-921, 1999.
159. Sies H. Biochemistry of oxidative stress. Angewandte Chemie 25: 1058-1071, 1986.
160. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol 4: 180-183, 2015.
161. Simms CL, Hudson BH, Mosior JW, Rangwala AS, and Zaher HS. An active role for the ribosome in determining the fate of oxidized mRNA. Cell Rep 9: 1256-1264, 2014.
162. Souza JM, Choi I, Chen Q, Weisse M, Daikhin E, Yudkoff M, Obin M, Ara J, Horwitz J, and Ischiropoulos H. Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys 380: 360-366, 2000.
163. Souza JM, Peluffo G, and Radi R. Protein tyrosine nitration-functional alteration or just a biomarker Free Radic Biol Med 45: 357-366, 2008.
164. Spickett CM, Wiswedel I, Siems W, Zarkovic K, and Zarkovic N. Advances in methods for the determination of biologically relevant lipid peroxidation products. Free Radic Res 44: 1172-1202, 2010.
165. Spiteller G. Linoleic acid peroxidation-the dominant lipid peroxidation process in low density lipoprotein-and its relationship to chronic diseases. Chem Phys Lipids 95: 105-162, 1998.
166. Stadtman ER. Protein modification in aging. J Gerontol 43: B112-B120, 1988.
167. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL. Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
168. Stocker R and Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004.
169. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, and Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22: 76-87, 2006.
170. Szabó-Taylor KÉ , Eggleton P, Turner CAL, Faro MLL, Tarr JM, Tóth S, Whiteman M, Haigh RC, Littlechild JA, and Winyard PG. Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial perox-iredoxin 2, compared with healthy human lymphocytes. Int J Biochem Cell Biol 44: 1223-1231, 2012.
171. Takahashi M, Hoshino H, Kushida K, Kawana K, and Inoue T. Direct quantification of pentosidine in urine and serum by HPLC with column switching. Clin Chem 42: 1439-1444, 1996.
172. Tanaka M, Chock PB, and Stadtman ER. Oxidized messenger RNA induces translation errors. Proc Natl Acad Sci USA 104: 66-71, 2007.
173. Teerlink T, Luo Z, Palm F, and Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 60: 448-460, 2009.
174. Thome J, Münch G, Mü ller R, Schinzel R, Kornhuber J, Blum-Degen D, Sitzmann L, Rösler M, Heidland A, and Riederer P. Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci 59: 679-685, 1996.
175. Thukkani AK, McHowat J, Hsu F-F, Brennan M-L, Hazen SL, and Ford DA. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108: 3128-3133, 2003.
176. Totan Y, Yag ci R, Bardak Y, Ozyurt H, Kendir F, Yilmaz G, Sahin S, and Sahin Tig U. Oxidative macromolecular damage in age-related macular degeneration. Curr Eye Res 34: 1089-1093, 2009.
177. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, and Isenovic ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci52: 70-85, 2015.
178. Tsikas D and Duncan MW. Mass spectrometry and 3-nitrotyrosine: strategies, controversies, and our current perspective. Mass Spectrom Rev 33: 237-276, 2014.
179. Tsimikas S. Measures of oxidative stress. Clin Lab Med 26: 571-590, v-vi, 2006.
180. Tsimikas S, Lau HK, Han K-R, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, and Strauss BH. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized lowdensity lipoprotein. Circulation 109: 3164-3170, 2004.
181. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, and Stadtman ER. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 324: 241-248, 1995.
182. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano J-C, Muzykantov V, Penn MS, Hazen SL, Weisel JW, and Ischiropoulos H. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 279: 8820-8826, 2004.
183. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
184. Vallance P, Leone A, Calver A, Collier J, and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 Suppl 12: S60-S62, 1992.
185. van der Vliet A, Eiserich JP, Halliwell B, and Cross CE. Formation of reactive nitrogen species during peroxidasecatalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 272: 7617-7625, 1997.
186. Vita JA, Brennan M-L, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF, and Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110: 1134-1139, 2004.
187. Wacker BK, Albert CJ, Ford BA, and Ford DA. Strategies for the analysis of chlorinated lipids in biological systems. Free Radic Biol Med 59: 92-99, 2013.
188. Waeg G, Dimsity G, and Esterbauer H. Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins. Free Radic Res 25: 149-159, 1996.
189. Wakita C, Honda K, Shibata T, Akagawa M, and Uchida K. A method for detection of 4-hydroxy-2-nonenal adducts in proteins. Free Radic Biol Med 51: 1-4, 2011.
190. Wayenberg J-L, Ransy V, Vermeylen D, Damis E, and Bottari SP. Nitrated plasma albumin as a marker of nitrative stress and neonatal encephalopathy in perinatal asphyxia. Free Radic Biol Med 47: 975-982, 2009.
191. Weimann A, Belling D, and Poulsen HE. Measurement of 8-oxo-2"-deoxyguanosine and 8-oxo-2-"deoxyadenosine in DNA and human urine by high performance liquid chromatography-electrospray tandem mass spectrometry. Free Radic Biol Med 30: 757-764, 2001.
192. Weimann A, Belling D, and Poulsen HE. Quantification of 8-oxo-guanine and guanine as the nucleobase, nucleoside and deoxynucleoside forms in human urine by highperformance liquid chromatography-electrospray tandem mass spectrometry. Nucleic Acids Res 30: E7, 2002.
193. Weimann A, Broedbaek K, Henriksen T, Stovgaard ES, and Poulsen HE. Assays for urinary biomarkers of oxidatively damaged nucleic acids. Free Radic Res 46: 531-540, 2012.
194. WHO. Biomarkers in Risk assessment: Validity and Validation. Geneva: WHO, 2001.
195. Witko-Sarsat V, Nguyen Khoa T, Jungers P, Druëke T, and Descamps-Latscha B. Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Adv Nephrol Necker Hosp 28: 321-341, 1998.
196. Wu T, Willett WC, Rifai N, Shai I, Manson JE, and Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women J Am Coll Cardiol 48: 973-979, 2006.
197. Yamakura F, Taka H, Fujimura T, and Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 273: 14085-14089, 1998.
198. Yang H, Wang W, Zhang Y, Zhao J, Lin E, Gao J, and He J. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer 12: 166-171, 2011.
199. Yi D, Ingelse BA, Duncan MW, and Smythe GA. Quantification of 3-nitrotyrosine in biological tissues and fluids: generating valid results by eliminating artifactual formation. J Am Soc Mass Spectrom 11: 578-586, 2000.
200. Yin H and Porter NA. New insights regarding the autoxidation of polyunsaturated fatty acids. Antioxid Redox Signal 7: 170-184, 2005.
201. Yodoi J and Maeda M. Discovery of ATL: an odyssey in restrospect. Int J Hematol 94: 423-428, 2011.